Team:RAMNOTIREN CALGARY/References

From 2014hs.igem.org

(Difference between revisions)
 
(4 intermediate revisions not shown)
Line 260: Line 260:
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY‎" id="homelink">Home</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY‎" id="homelink">Home</a></li>
-
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Team" id="teamlink">Team</a>
+
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Members" id="teamlink">Team</a>
<ul>
<ul>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Members">Members</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Members">Members</a></li>
-
<li><a href="https://igem.org/Team.cgi" target="_blank">Official Profile</a></li>
+
<li><a href="https://igem.org/Team.cgi?id=1295" target="_blank">Official Profile</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/AboutCMHS">About CMHS</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/AboutCMHS">About CMHS</a></li>
</ul>
</ul>
</li>
</li>
-
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project" id="projectlink">Project </a>
+
                                  <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content" id="projectlink">Project </a>
<ul>
<ul>
-
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content">Content</a></li>
+
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Content">Overview</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/HumanPractices">Human Practices</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/HumanPractices">Human Practices</a></li>
 +
                                                <li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Project/Safety">Safety</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/References">References</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/References">References</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Attributions">Attributions</a></li>
<li><a href="https://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/Attributions">Attributions</a></li>
Line 287: Line 288:
</div>
</div>
</header>
</header>
-
  </h2>
+
 
-
    <p>Pellentesque habitant morbi tristique senectus et netus et
+
<div id="reference">
-
    malesuada fames ac turpis egestas. Vestibulum tortor quam,
+
<h3>References</h3><br>
-
    feugiat vitae, ultricies eget, tempor sit amet, ante. Donec eu
+
 
-
    libero sit amet quam egestas semper. Aenean ultricies mi vitae
+
A New Strategy in the War on Cancer. (2009, October 1). . Retrieved , from http://www.ted.com/talks/david_agus_a_new_strategy_in_the_war_on_cancer.html<br>
-
    est. Mauris placerat eleifend leo. Quisque sit amet est et sapien
+
Targeted Cancer Therepy. (n.d.). . Retrieved , from
-
    ullamcorper pharetra. Vestibulum erat wisi, condimentum sed,
+
http://www.cancer.org/acs/groups/cid/documents/webcontent/003024-pdf.pdf<br>
-
    commodo vitae, ornare sit amet, wisi. Aenean fermentum, elit eget
+
http://new.ted.com/playlists/63/a_cure_for_cancer<br>
-
    tincidunt condimentum, eros ipsum rutrum orci, sagittis tempus
+
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC205287/ <br>
-
    lacus enim ac dui. Donec non enim in turpis pulvinar facilisis.
+
http://biotech.szbk.u-szeged.hu/RG_Jegyzet/pBADg3_man.pdf <br>
-
    Ut felis. Praesent dapibus, neque id cursus faucibus, tortor
+
http://www.wisegeek.com/what-is-endostatin.htm <br>
-
    neque egestas augue, eu vulputate magna eros eu erat. Aliquam
+
 
-
    erat volutpat. Nam dui mi, tincidunt quis, accumsan porttitor,
+
<h3>Papers:</h3>
-
    facilisis luctus, metus.</p>
+
Hooke, A., Oeschger, M. P., Zeligs, B., & Bellanti, J. Ideal Target Organism for Quantitative Bactericidal Assays. Infection and Immunity.<br>
 +
Anti-angiogenesis mediated by angiostatin K1–3, K1–4 and K1–4.5; Anti Angiogenesis mediated by angiostatin.<br> Endothelium and Vascular Development<br>
 +
Nussenbaum, F., & Herman, I. N. Tumor Angiogenesis . Insights and Innovations, 2010.<br>
 +
Antiangiogenic peptides and proteins; https://d2l.cbe.ab.ca/d2l/le/content/306178/viewContent/3812058/View
 +
Recombinant Human Angiostatin by Twice-Daily Subcutaneous Injection in Advanced Cancer<br>  
 +
 +
 
</body>
</body>
</html>
</html>

Latest revision as of 03:59, 21 June 2014

References


A New Strategy in the War on Cancer. (2009, October 1). . Retrieved , from http://www.ted.com/talks/david_agus_a_new_strategy_in_the_war_on_cancer.html
Targeted Cancer Therepy. (n.d.). . Retrieved , from http://www.cancer.org/acs/groups/cid/documents/webcontent/003024-pdf.pdf
http://new.ted.com/playlists/63/a_cure_for_cancer
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC205287/
http://biotech.szbk.u-szeged.hu/RG_Jegyzet/pBADg3_man.pdf
http://www.wisegeek.com/what-is-endostatin.htm

Papers:

Hooke, A., Oeschger, M. P., Zeligs, B., & Bellanti, J. Ideal Target Organism for Quantitative Bactericidal Assays. Infection and Immunity.
Anti-angiogenesis mediated by angiostatin K1–3, K1–4 and K1–4.5; Anti Angiogenesis mediated by angiostatin.
Endothelium and Vascular Development
Nussenbaum, F., & Herman, I. N. Tumor Angiogenesis . Insights and Innovations, 2010.
Antiangiogenic peptides and proteins; https://d2l.cbe.ab.ca/d2l/le/content/306178/viewContent/3812058/View Recombinant Human Angiostatin by Twice-Daily Subcutaneous Injection in Advanced Cancer

Retrieved from "http://2014hs.igem.org/Team:RAMNOTIREN_CALGARY/References"